Group 1 - The stock of Yaojie Ankang-B (02617) rose over 10%, reaching a new high of 30.7 HKD, which is an increase of over 130% from the IPO price of 13.15 HKD [1] - As of the report, the stock was up 8.83% at 30.2 HKD, with a trading volume of 24.18 million HKD and a market capitalization that briefly exceeded 12 billion HKD [1] - Yaojie Ankang announced that its self-developed multi-target kinase inhibitor, TT-00420, received Fast Track designation from the FDA for the treatment of metastatic castration-resistant prostate cancer [1] Group 2 - According to Frost & Sullivan, the global CCA drug market is expected to reach 2 billion USD by 2024, with a compound annual growth rate (CAGR) of 16.2% from 2019 to 2024 [2] - The market is projected to grow to 3.2 billion USD by 2027, with a CAGR of 17.1% from 2024 to 2027, and further increase to 4.6 billion USD by 2030, with a CAGR of 12.8% from 2027 to 2030 [2] - The company is a leader in the niche industry, with Tinengotinib being the first and only FGFR inhibitor entering the registration clinical stage for treating recurrent or refractory cholangiocarcinoma patients [2]

药捷安康是一家以临床需求为导向、处于注册性临床阶段的生物制药公司,专注于发现及开发肿瘤、炎 症及心脏代谢疾病小分子创新疗法。凭借本身全面融合的内部"ACE"方法,公司已建立六款临床阶段候 选产品及一款临床前阶段候选产品的管线,并计划持续拓展。公司专注于开发具有重大临床价值的同类 首创或同类最佳候选药物,以满足全球未被满足的临床需求。其核心产品Tinengotinib(TT-00420)是一款 处 于 注 册 性 临 床 阶 段 、 自 主 研 发 的 独 特 多 靶 点 激 酶 ("MTK") 抑 制 剂 ( 主 要 靶 向 三 个 关 键 通 路:FGFR/VEGFR、JAK和Aurora激酶)。截至目前,Tinengotinib正在进行两项关键性/注册性临床试验,用 于治疗在过往接受FGFR抑制剂治疗后疾病发生进展的胆管癌("CCA")患者,分别在中国和国际多中心临 床试验("MRCT")进行。 2025年6月23日,创投集团合作子基金南京紫金先进制造产业股权投资中心(有限合伙)(以下简称"紫金先 进制造基金")投资企业——药捷安康(南京)科技股份有限公司(以下简称"药捷安康") 正式于香港联合交 易所有 ...

如果把多靶点激酶比喻为人体内细胞的信号"开关"，那么，多靶点激酶抑制剂的功效便是点对点阻止有 故障的"开关"，通过独特的机制来发挥抗肿瘤作用。药捷安康自主研发的核心产品Tinengotinib，正是 这样一款重要的多靶点激酶抑制剂。 据了解，目前，Tinengotinib已在中美两地开展了多项针对胆管癌、前列腺癌、乳腺癌等实体瘤的临床 试验，并被国家药监局批准纳入突破性治疗品种名单，获得美国FDA授予的用于治疗胆管癌的"孤儿药 认证"（指针对罕见病开发的药物所获得的一种资格认定）。 极具竞争力的自主研发产品、不俗的临床进度、国际化视野……作为小分子创新药研发领域的"多边形 战士"，近年来，药捷安康也吸引了资本市场接连抛来的"橄榄枝"。截至目前，企业共完成9轮融资，融 资总额超17亿元。 "这次在港交所主板成功挂牌上市，可以说是我们竞逐资本市场的又一个崭新起点。在这个过程中，南 京江北新区不仅给予我们'真金白银'的支持，还在各个阶段提供贴心和高效的服务，加速了企业的上市 步伐。对此，我们心怀感恩，对企业的发展充满期待。"药捷安康相关负责人说。 记者进一步了解到，其所说的"真金白银"，正是南京江北新区创新成立的境 ...

Core Viewpoint - The article highlights the recent IPO of three companies on the Hong Kong Stock Exchange, with a particular focus on药捷安康, which experienced a significant stock price increase on its debut despite being in a loss-making position and lacking approved products for commercial sale [1][2]. Group 1: Company Overview - 药捷安康 is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies for cancer, inflammation, and cardiovascular metabolic diseases [1]. - The company was founded in 2014 and had previously attempted to list on the Hong Kong Stock Exchange in 2021 but did not proceed [3]. Group 2: IPO Details - 药捷安康 priced its shares at HKD 13.15, issuing 15.281 million shares, with a public offering oversubscription rate of 3,419.87 times [2]. - The company raised approximately HKD 1.61 billion from the IPO, with plans to allocate 90% of the net proceeds to fund a multi-regional Phase III clinical trial for its core product, Tinengotinib [4]. Group 3: Financial Performance - 药捷安康 reported cumulative losses exceeding HKD 618 million over the past two years, with projected revenues of HKD 1.18 million in 2023 and zero in 2024, alongside significant R&D costs [3]. - The company has utilized about 72% of the funds raised from previous investments prior to the IPO [3]. Group 4: Future Plans - Following the IPO, 药捷安康 aims to accelerate its internationalization and commercialization efforts, including the establishment of an internal commercial team in China [2].

2023年、2024年，药捷安康分别录得净亏损约3.43亿元、2.75亿元。 据招股书介绍，药捷安康是一家以临床需求为导向、处于注册阶段的生物制药公司，专注于发现及开发肿瘤、炎症及心血管疾病小分子创新疗法。药捷安康 方面称，该公司已自主发现及开发一种核心产品、建立五种临床阶段候选产品及一种临床前阶段候选产品的管线。 其中，药捷安康的核心产品Tinengotinib是一种独特的多靶点激酶抑制剂，主要靶向三个关键通路。截至最后实际可行日期，Tinengotinib正进行两项关键性 ╱注册临床试验，用于治疗在过往接受FGFR抑制剂治疗后疾病发生进展的胆管癌。 截至目前，药捷安康暂未实现商业化。为了开展及支持临床前及临床研究，药捷安康与合约研究机构（CRO）达成了合作。2023年、2024年，CRO产生的 费用分别约为1.92亿元、1.46亿元，其中73.1%及81.7%的费用归因于Tinengotinib的研发。 2023年、2024年，药捷安康的研发成本分別约为3.45亿元、2.44亿元，分别占其经营费用总额（即研发成本及管理费用）的89.8%及83.6%。其中，核心产品 Tinengotinib应占的研发费用金 ...

Core Viewpoint - Yaojie Ankang (Nanjing) Technology Co., Ltd. has successfully listed on the Hong Kong Stock Exchange, with its stock closing at HKD 23.50, representing a 78.71% increase from its initial offering price of HKD 13.15 [1][4]. Group 1: Share Issuance and Financials - The total number of shares issued by Yaojie Ankang is 15,281,000, with 3,057,000 shares allocated for public offering in Hong Kong and 12,224,000 shares for international offering [2]. - The total proceeds from the share issuance amount to HKD 200.95 million, with net proceeds of HKD 161.34 million after deducting estimated listing fees of HKD 39.61 million [4][5]. - The company currently has 396,897,633 shares outstanding at the time of listing [2]. Group 2: Use of Proceeds - Approximately 90% of the net proceeds will be allocated to the research and development of the company's core product, Tinengotinib, while the remaining 10% will be used for general working capital and corporate purposes [5]. Group 3: Company Overview and Financial Performance - Yaojie Ankang is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule innovative therapies for oncology, inflammation, and cardiovascular metabolic diseases [5]. - The company reported no revenue for 2023 and projected revenue of RMB 1.2 million for 2024, with no products currently approved for commercial sale [6]. - The company incurred losses of RMB 343.4 million in 2023 and RMB 274.6 million in 2024, totaling RMB 618 million over the two years, primarily due to high R&D costs and management expenses [6][7].

点击蓝字，关注我们 基本情况 · 招股时间 : 2025年6月13日至6月18日（共5天） · 上市时间 : 2025年6月23日 · 发行规模 : 全球发售股数: 1528.1万股; 香港公开发售占10% (约152.81万股); 国际发售占90% (约 1375.29万股)。 · 发行定价 ：13.15港元/股 · 每手股数 ：500，一手入场费约6641.31港元（含手续费） · 绿鞋 ：有 · 保荐人 ：中信证券（香港）有限公司，华泰金融控股（香港）有限公司 · 基石投资者 ：江北医药，华盛敦行，科瓴安，药石地平线，康方生物。合计认购1.3亿港元，占全球 发售股份的64.06%。 | | 575.10万 37.63% | | | --- | --- | --- | | 华盛敦行有限公司 | 164.30 万 10.75% | | | 科瓴安（香港）科技有限公司 O | 82.15 万 | 5.38% | | 药石地平线资本有限公司 | 82.15 万 | 5.38% | | 康方生物科技(开曼)有限公司 | 75.25 万 | 4.92% | · 截至发稿，孖展超700倍，非常火爆，确定性高，但相应的 ...

6月13日，药捷安康（南京）科技股份有限公司（下称"药捷安康"，HK:02617）披露发售公告，于6月 13日至6月18日招股，拟全球发售1528.1万股H股，每股发售价13.15港元，预计将于2025年6月23日在港 交所上市。 其中，药捷安康的核心产品Tinengotinib是一种独特的多靶点激酶抑制剂，主要靶向三个关键通路。截 至最后实际可行日期，Tinengotinib正进行两项关键性╱注册临床试验，用于治疗在过往接受FGFR抑制 剂治疗后疾病发生进展的胆管癌。 同时，药捷安康正在探索将Tinengotinib用于治疗转移性去势抵抗性前列腺癌、乳腺癌、胆道系统癌症 及泛FGFR实体瘤，并已完成该等适应症的II期临床研究。此外，该公司拟于II期试验中评估Tinengotinib 联合卡度尼利单抗或依沃西单抗治疗肝细胞癌的效果。 截至目前，药捷安康暂未实现商业化。为了开展及支持临床前及临床研究，药捷安康与合约研究机构 （CRO）达成了合作。2023年、2024年，CRO产生的费用分别约为1.92亿元、1.46亿元，其中73.1%及 81.7%的费用归因于Tinengotinib的研发。 2023年、202 ...

（原标题：药捷安康(02617.HK) 6月13日—6月18日招股） 药捷安康(02617.HK)发布公告，公司拟全球发售1528.10万股股份，其中香港发售股份152.85万股，国际发售股份1375.25万股，另有229.20万股超 额配股权。招股日期为6月13日至6月18日，最高发售价13.15港元，每手买卖单位500股，入场费约6641.31港元。 全球发售预计募资总额为2.01亿港元，募资净额1.61亿港元，募资用途为用于为公司的核心产品Tinengotinib正在进行单药治疗CCA的多区域注册 III期临床试验提供资金；用于公司的一般营运资金及一般公司用途。 公司2022年度、2023年度、2024年度截至12月31日止，净利润分别为-2.52亿元、-3.43亿元、-2.75亿元。（数据宝） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 公司引入江北医药科技（香港）有限公司、华盛敦行有限公司、药石地平线资本有限公司、科瓴安（香港）科技有限公司、康方生物科技（开 曼）有限公司等基石投资者，将以发售价共认购数量下限约978.95万股可购买发售的股份。 药捷安康预计于2025年6月23日在 ...

Group 1 - The company,药捷安康-B (02617), plans to conduct a global offering of 15.281 million H shares from June 13 to June 18, 2025, with a share price of HKD 13.15 and a 15% over-allotment option [1] - The company focuses on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, with a mission to provide innovative and differentiated treatment solutions globally [1] - The company has established a pipeline of six clinical-stage candidates and one preclinical candidate, aiming to expand its pipeline further through in-depth research in translational medicine and drug design [1] Group 2 - The company has entered into cornerstone investment agreements with five cornerstone investors, who have agreed to subscribe for shares totaling approximately HKD 130 million [2] - Based on the share price of HKD 13.15, cornerstone investors will acquire approximately 978.95 million shares [2] - The company estimates a net proceeds of approximately HKD 161 million from the global offering, with 90% allocated to fund a multi-regional Phase III clinical trial for its core product, Tinengotinib, and 10% for general operational expenses [2]